Scholars@Duke
Susanna Naggie

Susanna Naggie

Professor of Medicine
Medicine, Infectious Diseases
susanna.naggie@duke.edu
Box 17969, Durham, NC 27715
300 West Morgan St, Suite 800, Durham, NC 27701

Selected Publications

Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure.

Journal Article J Viral Hepat · December 2024 A subset of patients with chronic hepatitis C virus (HCV) infection demonstrate liver enzyme elevation (LEE) after achieving sustained virologic response (SVR). Risk factors for LEE are not well characterised. We conducted a single-centre retrospective coh ... Full text Link to item Cite

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls.

Journal Article Aliment Pharmacol Ther · November 2024 BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in people with HIV (PWH). The morphological spectrum of MASLD compared to matched controls and of the correlation between the NAFLD activity score (NAS) and fibrosis sta ... Full text Link to item Cite

Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.

Journal Article JAMA Netw Open · October 1, 2024 IMPORTANCE: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain. OBJECTIVE: To assess the effectiveness of montelukast compared with placebo in treating outpatients with mild to moderate COVI ... Full text Link to item Cite

Cumulative Tenofovir Exposure Among Patients With HIV/Hepatitis B Coinfection With Differential Viral Suppression.

Journal Article Clin Infect Dis · September 26, 2024 This case-control study explored cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatis B virus (HIV/HBV) coinfection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels in d ... Full text Link to item Cite

Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living With HIV and Steatotic Liver Disease.

Journal Article Am J Gastroenterol · August 1, 2024 INTRODUCTION: Steatotic liver disease is common in people with HIV (PWH). Identifying those with advanced fibrosis (AF, bridging fibrosis or cirrhosis), F3-4, is important. We aimed to examine the performance of FIB-4 and nonalcoholic fatty liver disease ( ... Full text Link to item Cite

Effects of Food Insecurity on Hepatic Steatosis and Fibrosis in People With HIV.

Journal Article Clin Gastroenterol Hepatol · July 2024 BACKGROUND & AIMS: Food insecurity (FI) is a risk factor for nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis in the general population, but its impact on liver disease in people with HIV (PWH) is unknown. METHODS: We examined the association ... Full text Link to item Cite

Vaccine Effectiveness Against Long COVID in Children.

Journal Article Pediatrics · April 1, 2024 OBJECTIVES: Vaccination reduces the risk of acute coronavirus disease 2019 (COVID-19) in children, but it is less clear whether it protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in children aged 5 to 17 years. METHO ... Full text Link to item Cite

Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.

Journal Article Aliment Pharmacol Ther · March 2024 BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD. AIMS: To assess the effects of this new nomenclature on the prevalence and distribution of different SLD categories in ... Full text Link to item Cite

Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative.

Journal Article J Clin Transl Sci · 2024 This manuscript addresses a critical topic: navigating complexities of conducting clinical trials during a pandemic. Central to this discussion is engaging communities to ensure diverse participation. The manuscript elucidates deliberate strategies employe ... Full text Link to item Cite

Duke Research at Pickett: The Evolution of a Free-standing Research Site Partnering with Communities Toward Health Equity Advancement

Journal Article Journal of Clinical and Translational Science · January 1, 2024 While clinical research intends to improve health outcomes for all, access to research participation is often limited and inequitable. Geographic proximity is a recognized barrier, thus, systemic infrastructure solutions through federal programs including ... Full text Cite

Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.

Journal Article JAMA · December 26, 2023 IMPORTANCE: The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. OBJECTIVE: To assess the effectiveness of fluvoxamine, 100 mg twice daily, compared with placebo, for treatin ... Full text Link to item Cite

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.

Journal Article Clin Infect Dis · December 15, 2023 While the coronavirus disease 2019 (COVID-19) pandemic continues to present global challenges, sufficient time has passed to reflect on lessons learned and use those insights to inform policy and approaches to prepare for the next pandemic. In May 2022, th ... Full text Link to item Cite

A telehealth-delivered intervention to extend the veteran HIV treatment cascade for cardiovascular disease prevention: V-EXTRA-CVD study protocol for a randomized controlled trial.

Journal Article HIV Res Clin Pract · December 2023 Background: Veterans living with HIV have up to twice the risk of atherosclerotic cardiovascular disease (ASCVD) compared to those without HIV.Objective: Our study seeks to test a non-physician led virtual self-management implementation strategy to reduce ... Open Access Link to item Cite

Fatty Liver Disease: Enter the Metabolic Era.

Journal Article Curr HIV/AIDS Rep · December 2023 PURPOSE OF REVIEW: The goal of this review is to summarize the recent literature linking HIV to metabolic dysfunction-associated steatotic liver disease (MASLD). This is a pressing issue due to the scale of the MASLD epidemic and the urgent need for preven ... Full text Link to item Cite

Revisions to Medication Description and Manufacturer

Journal Article JAMA · October 24, 2023 Full text Cite

Vaccine Effectiveness Against Long COVID in Children: A Report from the RECOVER EHR Cohort.

Journal Article medRxiv · September 28, 2023 OBJECTIVE: Vaccination reduces the risk of acute COVID-19 in children, but it is less clear whether it protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in children aged 5-17 years. METHODS: This retrospective cohort s ... Full text Link to item Cite

Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.

Journal Article N Engl J Med · September 21, 2023 BACKGROUND: The effectiveness of inhaled glucocorticoids in shortening the time to symptom resolution or preventing hospitalization or death among outpatients with mild-to-moderate coronavirus disease 2019 (Covid-19) is unclear. METHODS: We conducted a dec ... Full text Link to item Cite

Effect of Higher-Dose Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.

Journal Article medRxiv · September 13, 2023 BACKGROUND: The impact of fluvoxamine in reducing symptom duration among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) remains uncertain. Our objective was to assess the effectiveness of fluvoxamine 100 mg twice daily, compared with ... Full text Link to item Cite

Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases.

Journal Article Am J Kidney Dis · September 2023 The transplantation of organs from donors with hepatitis C virus (HCV) infection into uninfected recipients has expanded the available organ donor pool. With the advancement of direct-acting antivirals (DAAs), high rates of cure among transplant recipients ... Full text Link to item Cite

Incorrect Nonauthor Collaborator Name.

Journal Article JAMA · August 15, 2023 Full text Link to item Cite

Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review.

Journal Article Clin Infect Dis · August 14, 2023 Following the discovery of hepatitis C virus (HCV) in 1989, 3 decades of basic, translational, and clinical research culminated in the development of direct-acting antiviral (DAA) therapy-curative oral treatment for HCV infection. The availability of DAA t ... Full text Link to item Cite

Transplanting hepatitis B surface antigen-positive livers in the United States: Outcomes and opportunities.

Journal Article Am J Transplant · August 2023 Livers from donors with positive hepatitis B surface antigens (HBsAg+) have been used to expand the donor pool; however, outcome data are limited. We aim to evaluate survival following liver transplant (LT) from HBsAg+ donors. Using the United Network for ... Full text Link to item Cite

Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019.

Journal Article JAMA Netw Open · August 1, 2023 IMPORTANCE: Despite aging-related comorbidities representing a growing threat to quality-of-life and mortality among persons with HIV (PWH), clinical guidance for comorbidity screening and prevention is lacking. Understanding comorbidity distribution and s ... Full text Link to item Cite

Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.

Journal Article BMJ Open · June 16, 2023 OBJECTIVE: We studied the safety and efficacy of hydroxychloroquine (HCQ) as pre-exposure prophylaxis for COVID-19 in healthcare workers (HCWs), using a meta-analysis of randomised controlled trials (RCTs). DATA SOURCES: PubMed and EMBASE databases were se ... Full text Link to item Cite

Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).

Conference Int J Infect Dis · April 2023 OBJECTIVES: To determine whether hydroxychloroquine (HCQ) is safe and effective at preventing COVID-19 infections among health care workers (HCWs). METHODS: In a 1: 1 randomized, placebo-controlled, double-blind, parallel-group, superiority trial at 34 US ... Full text Link to item Cite

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.

Journal Article JAMA · March 21, 2023 IMPORTANCE: It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19. OBJECTIVE: To evaluate the effectiveness of ivermectin at a max ... Full text Link to item Cite

Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras.

Journal Article Clin Infect Dis · February 18, 2023 BACKGROUND: People with human immunodeficiency virus (HIV) with and without hepatitis C virus (HCV) coinfection had poor outcomes after liver transplant (LT). Integrase strand transfer inhibitors (INSTIs) and direct-acting antivirals (DAAs) have changed th ... Full text Link to item Cite

The Effect of Menopausal Status, Age, and Human Immunodeficiency Virus (HIV) on Non-AIDS Comorbidity Burden Among US Women.

Journal Article Clin Infect Dis · February 8, 2023 Menopause may impact the earlier onset of aging-related comorbidities among women with versus without human immunodeficiency virus (HIV). We found that menopausal status, age, and HIV were independently associated with higher comorbidity burden, and that H ... Full text Link to item Cite

Liver Inflammation Is Common and Linked to Metabolic Derangements in Persons With Treated Human Immunodeficiency Virus (HIV).

Journal Article Clin Infect Dis · February 8, 2023 BACKGROUND: We sought to characterize in people with human immunodeficiency virus (PWH) the potential etiologies of elevated alanine aminotransferase (ALT) levels, which are common and often unexplained. METHODS: Participants from the longitudinal observat ... Full text Link to item Cite

Cumulative Human Immunodeficiency Virus (HIV)-1 Viremia Is Associated With Increased Risk of Multimorbidity Among US Women With HIV, 1997-2019.

Journal Article Open Forum Infect Dis · February 2023 BACKGROUND: To evaluate the effect of cumulative human immunodeficiency virus (HIV)-1 viremia on aging-related multimorbidity among women with HIV (WWH), we analyzed data collected prospectively among women who achieved viral suppression after antiretrovir ... Full text Open Access Link to item Cite

Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Journal Article JAMA · January 24, 2023 IMPORTANCE: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild to moderate symptomatic COVID-19 is unclear. OBJECTIVE: To evaluate the efficacy of low-dose fluvoxamine (50 mg twice daily) for ... Full text Link to item Cite

Incorrect Author Name.

Journal Article JAMA · January 10, 2023 Full text Link to item Cite

ACTIV-6: Operationalizing a decentralized, outpatient randomized platform trial to evaluate efficacy of repurposed medicines for COVID-19.

Journal Article J Clin Transl Sci · 2023 Despite the availability of vaccinations, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause Coronavirus Disease 2019 (COVID-19) infection with a spectrum of disease in the acute setting. Transmission, infection, and severe dis ... Full text Link to item Cite

Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.

Journal Article medRxiv · December 15, 2022 BACKGROUND: Whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) remains unknown. Our objective was to evaluate the ... Full text Link to item Cite

Secondary hemophagocytic lymphohistiocytosis due to Heartland virus.

Journal Article BMJ Case Rep · December 8, 2022 An older man from the mid-Southeastern USA presented with acute onset of fever, fatigue, and non-bloody diarrhoea. There was high suspicion for tick-borne illness given exposure history, clinical presentation and laboratory abnormalities. Despite prompt tr ... Full text Link to item Cite

Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.

Journal Article medRxiv · November 1, 2022 BACKGROUND: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic coronavirus disease 2019 (COVID-19) is unclear. DESIGN: ACTIV-6 is an ongoing, decentralized, ... Full text Link to item Cite

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Journal Article JAMA · October 2022 ImportanceThe effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown.ObjectiveTo evaluate the efficacy of ivermectin, 400 μg/kg, ... Full text Cite

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.

Journal Article medRxiv · August 11, 2022 BACKGROUND: The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the United States with mild-to-moderate symptomatic coronavirus disease 2019 (COVID-19) is unknown. OBJECTIVE: We evaluated the efficacy ... Full text Link to item Cite

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.

Journal Article medRxiv · August 11, 2022 BACKGROUND: The effectiveness of inhaled corticosteroids to shorten time to symptom resolution or prevent hospitalization or death among outpatients with mild-to-moderate coronavirus 2019 (Covid-19) is unclear. METHODS: ACTIV-6 is an ongoing, decentralized ... Full text Link to item Cite

A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.

Journal Article Lancet Gastroenterol Hepatol · April 2022 BACKGROUND: Despite widespread availability of direct-acting antivirals including generic formulations, limited progress has been made in the global adoption of hepatitis C virus (HCV) treatment. Barriers to treatment scale-up include availability and acce ... Full text Open Access Link to item Cite

COVID-19 Trials: Who Participates and Who Benefits?

Journal Article South Med J · April 2022 OBJECTIVES: The coronavirus disease 2019 (COVID-19) pandemic has disproportionately afflicted vulnerable populations. Older adults, particularly residents of nursing facilities, represent a small percentage of the population but account for 40% of mortalit ... Full text Open Access Link to item Cite

Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.

Journal Article Clin Gastroenterol Hepatol · February 2022 Nonalcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascu ... Full text Link to item Cite

Cumulative HIV-1 viremia is associated with multimorbidity among US women with HIV

Conference JOURNAL OF THE INTERNATIONAL AIDS SOCIETY · 2022 Cite

Development and evaluation of a novel training program to build study staff skills in equitable and inclusive engagement, recruitment, and retention of clinical research participants.

Journal Article J Clin Transl Sci · 2022 BACKGROUND: Adequate equitable recruitment of underrepresented groups in clinical research and trials is a national problem and remains a daunting challenge to translating research discoveries into effective healthcare practices. Engagement, recruitment, a ... Full text Open Access Link to item Cite

A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever).

Journal Article Contemp Clin Trials Commun · December 2021 INTRODUCTION: Coccidioidomycosis is a fungal infection endemic in the southwestern United States (US). Primary pulmonary coccidioidomycosis (PPC) is a leading cause of community-acquired pneumonia (CAP) in this region, although its diagnosis is often delay ... Full text Open Access Link to item Cite

Incident Non-AIDS Comorbidity Burden Among Women With or at Risk for Human Immunodeficiency Virus in the United States.

Journal Article Clin Infect Dis · October 5, 2021 BACKGROUND: Human immunodeficiency virus (HIV) infection may accelerate development of aging-related non-AIDS comorbidities (NACMs). The incidence of NACMs is poorly characterized among women living with HIV (WLWH). METHODS: WLWH and HIV-seronegative parti ... Full text Link to item Cite

Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform.

Journal Article Contemp Clin Trials · October 2021 BACKGROUND: The SARS CoV-2 virus has caused one of the deadliest pandemics in recent history, resulting in over 170 million deaths and global economic disruption. There remains an urgent need for clinical trials to test therapies for treatment and preventi ... Full text Open Access Link to item Cite

Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19.

Journal Article Ann Intern Med · August 2021 The development of the National Institutes of Health (NIH) COVID-19 Treatment Guidelines began in March 2020 in response to a request from the White House Coronavirus Task Force. Within 4 days of the request, the NIH COVID-19 Treatment Guidelines Panel was ... Full text Open Access Link to item Cite

COVID-19-Lessons Learned and Questions Remaining.

Journal Article Clin Infect Dis · June 15, 2021 In this article, the editors of Clinical Infectious Diseases review some of the most important lessons they have learned about the epidemiology, clinical features, diagnosis, treatment and prevention of SARS-CoV-2 infection and identify essential questions ... Full text Open Access Link to item Cite

The Prevalence and Burden of Non-AIDS Comorbidities Among Women Living With or at Risk for Human Immunodeficiency Virus Infection in the United States.

Journal Article Clin Infect Dis · April 26, 2021 BACKGROUND: The prevalence and burden of age-related non-AIDS comorbidities (NACMs) are poorly characterized among women living with HIV (WLWH). METHODS: Virologically suppressed WLWH and HIV-seronegative participants followed in the Women's Interagency HI ... Full text Link to item Cite

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.

Journal Article Nat Commun · April 15, 2021 Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine a ... Full text Open Access Link to item Cite

Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.

Journal Article J Viral Hepat · April 2021 Previous studies have reported an association of proton pump inhibitor (PPI) use and decreased sustained viral response rate (SVR) in patients taking ledipasvir/sofosbuvir (LDV/SOF). The relationship between PPI usage and SVR is less clear in patients with ... Full text Link to item Cite

New Therapeutics for Hepatitis B: The Road to Cure.

Journal Article Annu Rev Med · January 27, 2021 Chronic hepatitis B virus (HBV) infection impacts an estimated 257-291 million people globally. The current approach to treatment for chronic HBV infection is complex, reflecting a risk:benefit approach driven by the lack of an effective curative regimen. ... Full text Link to item Cite

Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.

Journal Article J Med Virol · December 2020 Hepatitis C virus (HCV) infections are more common among US veterans receiving care through Veterans Affairs (VA) Medical Centers than among the general population. Historically, HCV therapies had lower efficacy rates in VA patients, possibly due to common ... Full text Open Access Link to item Cite

Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection.

Journal Article J Infect Dis · November 13, 2020 BACKGROUND: Advanced liver disease due to hepatitis C virus (HCV) is a leading cause of human immunodeficiency virus (HIV)-related morbidity and mortality. There remains a need to develop noninvasive predictors of clinical outcomes in persons with HIV/HCV ... Full text Link to item Cite

Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment.

Journal Article Ann Pharmacother · November 2020 BACKGROUND: Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear whether ext ... Full text Link to item Cite

Cardiovascular Disease Risk Management in Persons With HIV: Does Clinician Specialty Matter?

Journal Article Open Forum Infect Dis · September 2020 BACKGROUND: The impact of clinician specialty on cardiovascular disease risk factor outcomes among persons with HIV (PWH) is unclear. METHODS: PWH receiving care at 3 Southeastern US academic HIV clinics between January 2014 and December 2016 were retrospe ... Full text Open Access Link to item Cite

Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020.

Journal Article MMWR Recomm Rep · July 24, 2020 Exposure to hepatitis viruses is a recognized occupational risk for health care personnel (HCP). This report establishes new CDC guidance that includes recommendations for a testing algorithm and clinical management for HCP with potential occupational expo ... Full text Open Access Link to item Cite

A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection.

Journal Article Hepatology · June 2020 BACKGROUND AND AIMS: Hepatitis C virus (HCV) and alcohol use are patient risk factors for accelerated fibrosis progression, yet few randomized controlled trials have tested clinic-based alcohol interventions. APPROACH AND RESULTS: A total of 181 patients w ... Full text Link to item Cite

Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression.

Journal Article Cell Mol Gastroenterol Hepatol · 2020 BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) occurs in the context of aberrant metabolism. Glutaminolysis is required for metabolic reprograming of hepatic stellate cells (HSCs) and liver fibrogenesis in mice. However, it is unclear how changes i ... Full text Open Access Link to item Cite

Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?

Journal Article Dig Dis Sci · December 2019 PURPOSE OF REVIEW: Liver disease is a leading cause of non-AIDS-related death in the HIV population since the introduction of highly active antiretroviral treatment (HAART). Recent studies suggest that patients with HIV are at high risk for nonalcoholic fa ... Full text Link to item Cite

Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus.

Journal Article Am J Cardiol · September 15, 2019 Improvement in survival in patients living with human immunodeficiency virus (PLHIV) has led to increased prevalence of cardiovascular disease. Whether HIV-associated immune dysfunction is associated with preclinical left ventricular (LV) dysfunction despi ... Full text Link to item Cite

Management of Hepatitis C in 2019.

Journal Article JAMA · July 23, 2019 Full text Link to item Cite

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

Journal Article Clin Infect Dis · July 18, 2019 BACKGROUND: Current guidelines for the management of hepatitis C virus (HCV) infections provide varying recommendations for the optimal treatment of acute HCV infections. There are limited data from small cohort studies to provide guidance on the best appr ... Full text Link to item Cite

Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations.

Journal Article Proteomics Clin Appl · May 2019 PURPOSE: In the interferon era of hepatitis C virus (HCV) therapies, genotype/subtype, cirrhosis, prior treatment failure, sex, and race predicted relapse. Our objective is to validate a targeted proteomics platform of 17 peptides to predict sustained viro ... Full text Link to item Cite

Treating HCV Infection: It Doesn't Get Much Better Than This.

Journal Article Top Antivir Med · January 2019 Direct-acting antiviral (DAA) regimens now allow treatment of previously untreated or treated (including prior DAA failures) patients with chronic hepatitis C virus (HCV) infection with 8 or 12 week regimens, largely without the use of ribavirin. Newer nex ... Link to item Cite

Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort.

Journal Article Open Forum Infect Dis · January 2019 BACKGROUND: Concomitant dosing of ledipasvir (LDV) and tenofovir disoproxil fumarate (TDF) results in an increased tenofovir (TFV) area under the curve (AUC). The aim of this study was to examine whether there was a correlation between the renal biomarkers ... Full text Open Access Link to item Cite

Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy.

Journal Article N C Med J · 2019 Prisoners in the United States are disproportionately affected by hepatitis C. Addressing the disease behind bars is crucial for curtailing the epidemic in the greater population. Effective strategies for testing and treatment are elucidated here. Recommen ... Full text Link to item Cite

Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Journal Article Clin Infect Dis · October 30, 2018 Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed a web-based proce ... Full text Link to item Cite

Outcomes for PrEP Users in the Southern US: Persistence and STIs

Conference AIDS RESEARCH AND HUMAN RETROVIRUSES · October 1, 2018 Link to item Cite

The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial.

Journal Article Contemp Clin Trials · September 2018 INTRODUCTION: Among patients with hepatitis C virus (HCV) infection, alcohol synergistically increases the risk of cirrhosis, hepatocellular carcinoma, and death. Randomized controlled trials of integrated models of HCV-alcohol treatment have been recommen ... Full text Link to item Cite

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.

Journal Article J Antimicrob Chemother · August 1, 2018 BACKGROUND: The nucleotide analogues tenofovir and sofosbuvir are considered to have low potential for drug interactions. OBJECTIVES: To determine the effect of sofosbuvir-based HCV treatment on plasma concentrations of tenofovir and cellular concentration ... Full text Link to item Cite

Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort.

Journal Article J Card Fail · August 2018 OBJECTIVE: The aim of this work was to investigate determinants of structural myocardial abnormalities in persons living with human immunodeficiency virus (PLWH). METHODS AND RESULTS: We reviewed archived transthoracic echocardiograms (TTEs) performed on P ... Full text Link to item Cite

Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection.

Journal Article Open Forum Infect Dis · July 2018 Liver disease is a leading cause of HIV-related mortality. Hepatitis C virus (HCV)-related fibrogenesis is accelerated in the setting of HIV coinfection, yet the mechanisms underlying this aggressive pathogenesis are unclear. We identified formalin-fixed p ... Full text Open Access Link to item Cite

Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.

Journal Article Clin Infect Dis · June 1, 2018 In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma ef ... Full text Link to item Cite

Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.

Journal Article Infect Dis Clin North Am · June 2018 The objective of this review is to consider how existing human immunodeficiency virus (HIV) infrastructure may be leveraged to inform and improve hepatitis C virus (HCV) treatment efforts in the HIV-HCV coinfected population. Current gaps in HCV care relev ... Full text Link to item Cite

IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.

Journal Article J Viral Hepat · May 2018 Interferon (IFN)-free direct-acting antiviral agents (DAAs) have revolutionized chronic hepatitis C virus (HCV) treatment; early studies suggest excellent efficacy in acute HCV. However, changes in innate immune responses during DAA therapy for acute HCV a ... Full text Link to item Cite

Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case-control study.

Journal Article Metabolomics · March 2018 INTRODUCTION: Persons living with HIV (PLWH) are at higher risk for cardiovascular disease (CVD) events than uninfected persons. Current risk-stratification methods to define PLWH at highest risk for CVD events are lacking. METHODS: Using tandem flow injec ... Full text Link to item Cite

Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome.

Journal Article Medicine (Baltimore) · February 2018 Cardiovascular disease (CVD) is an increasing cause of morbidity and mortality in human immunodeficiency virus (HIV)-infected adults; however, this population may be less likely to receive interventions during hospitalization for acute coronary syndrome (A ... Full text Open Access Link to item Cite

Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection.

Journal Article Open Forum Infect Dis · January 2018 BACKGROUND: Direct-acting antivirals (DAA) as curative therapy for hepatitis C virus (HCV) infection offer >95% sustained virologic response (SVR), including in patients with human immunodeficiency virus (HIV) infection. Despite improved safety and efficac ... Full text Open Access Link to item Cite

The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.

Journal Article Open Forum Infect Dis · January 2018 BACKGROUND: Direct acting antiviral hepatitis C virus (HCV) therapies are highly effective but costly. Wider adoption of an 8-week ledipasvir/sofosbuvir treatment regimen could result in significant savings, but may be less efficacious compared with a 12-w ... Full text Open Access Link to item Cite

Benefits of Direct-Acting Antivirals for Hepatitis C.

Journal Article Ann Intern Med · December 5, 2017 Full text Link to item Cite

Retreatment Options Following HCV Direct Acting Antiviral Failure.

Journal Article Curr Treat Options Infect Dis · December 2017 Despite the excellent efficacy of direct acting antivirals (DAA) for hepatitis C virus (HCV), treatment failures do occur. Until recently, retreatment decisions after DAA failure were influenced by the number of available agents, concerns about HCV drug re ... Full text Link to item Cite

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.

Journal Article Clin Infect Dis · July 1, 2017 BACKGROUND: A safe, simple, effective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains a medical need. We assessed the efficacy and safety of the NS5B poly ... Full text Link to item Cite

Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.

Conference Clin Infect Dis · April 15, 2017 BACKGROUND: Historically, acute hepatitis C virus (HCV) infection was treated with shorter durations of interferon-containing therapies. In the era of direct-acting antivirals (DAAs), it is unclear whether the efficacy of treatment achieved in chronic infe ... Full text Link to item Cite

Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Journal Article Drugs · February 2017 Hepatitis C virus (HCV) represents a significant global disease burden, with an estimated 130-150 million people worldwide living with chronic HCV infection. Within the six major clinical HCV genotypes, genotype 3 represents 22-30% of all infection and is ... Full text Link to item Cite

Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.

Journal Article Clin Gastroenterol Hepatol · February 2017 BACKGROUND & AIMS: We conducted a phase 4, open-label study with limited exclusion criteria to evaluate the safety and efficacy of sofosbuvir and ribavirin in veterans with hepatitis C virus genotype 2 infection, and compensated cirrhosis. This population ... Full text Link to item Cite

Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.

Journal Article Annu Rev Med · January 14, 2017 The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of ... Full text Link to item Cite

Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.

Journal Article Clin Infect Dis · January 1, 2017 Currently, 380 000-400 000 occupational exposures to blood-borne pathogens occur annually in the United States. The management for occupational HIV or hepatitis B virus exposures includes postexposure prophylaxis (PEP) when necessary; however, PEP is not r ... Full text Link to item Cite

Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time.

Journal Article Top Antivir Med · 2017 There is evidence that hepatitis C virus (HCV) infection, like HIV infection, may be associated with chronic inflammation, immune activation, and immune senescence, which contribute to increased risks for cardiometabolic or other diseases outside the liver ... Link to item Cite

Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study.

Journal Article Open Forum Infect Dis · 2017 BACKGROUND: The Simeprevir ObservatioNal Effectiveness across practice seTtings (SONET) study evaluated the real-world effectiveness of simeprevir-based treatment for hepatitis C virus (HCV) infection. METHODS: The SONET study was a phase 4, prospective, o ... Full text Open Access Link to item Cite

Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.

Conference J Viral Hepat · November 2016 A fixed-dose combination of ledipasvir and sofosbuvir (LDV/SOF) has been approved for treatment of HCV patients. We assessed the effect of LDV/SOF on patient-reported outcomes (PROs) in HIV-HCV-co-infected patients. Patient-reported outcomes data from HIV- ... Full text Link to item Cite

Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease.

Journal Article Open Forum Infect Dis · September 2016 Background.  Hepatitis C virus (HCV) infection is a leading cause of cirrhosis and the primary cause of liver transplantation in the United States, and coinfection with human immunodeficiency virus (HIV) increases the risk of comorbidities. However, health ... Full text Open Access Link to item Cite

Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.

Journal Article Clin Infect Dis · August 15, 2016 UNLABELLED: We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eigh ... Full text Link to item Cite

Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study.

Journal Article Clin Infect Dis · August 1, 2016 BACKGROUND: Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are associated with increased risk of cardiovascular disease (CVD). The potential impact of recently updated cholesterol guidelines on treatment of HIV- and HCV-infected ... Full text Link to item Cite

Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

Journal Article Clin Gastroenterol Hepatol · November 2015 The recent advances in hepatitis C virus (HCV) therapeutics have brought combinations of direct acting antiviral medications that offer interferon-free, well-tolerated regimens with sustained virologic response rates greater than 90% in clinical trials for ... Full text Link to item Cite

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Journal Article N Engl J Med · August 20, 2015 BACKGROUND: Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains an unmet medical need. METHODS: We conducted a multicenter, single-group, open-label study involving patients coinfe ... Full text Link to item Cite

Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.

Journal Article J Infect Dis · August 1, 2015 BACKGROUND: Sofosbuvir-containing regimens have been approved for treatment of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients. We assessed the effect of treatment with sofosbuvir and ribavirin on patient-reported ... Full text Link to item Cite

Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1

Journal Article JOURNAL OF THE INTERNATIONAL AIDS SOCIETY · July 1, 2015 Full text Link to item Cite

Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Journal Article HIV Med · April 2015 OBJECTIVES: Liver disease is increasingly recognized in HIV-positive individuals, even among those without viral hepatitis, partly as a result of the recent availability of noninvasive methods of liver fibrosis assessment. The objective of this substudy is ... Full text Link to item Cite

Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals.

Journal Article Open Forum Infect Dis · April 2015 We evaluated the impact of antiretroviral-induced dyslipidemia on hepatitis C virus (HCV) biogenesis in human immunodeficiency virus (HIV)/HCV coinfected patients. This study used serum samples from antiretroviral-naive HIV/HCV patients initiating their fi ... Full text Open Access Link to item Cite

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

Journal Article Hepatology · March 2015 UNLABELLED: Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to ... Full text Link to item Cite

The clinical management of HCV in the HIV-infected patient.

Journal Article Antivir Ther · 2015 Chronic hepatitis C affects an estimated 170 million persons worldwide and due to shared transmission routes many persons are coinfected with HIV. Since the advent of HAART, HIV patients have longer life expectancy and suffer fewer AIDS-related complicatio ... Full text Link to item Cite

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Journal Article JAMA · July 23, 2014 IMPORTANCE: Treatment of hepatitis C virus (HCV) infection in patients also infected with human immunodeficiency virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) and the need to use interferon. OBJECTIVE: To determ ... Full text Link to item Cite

[In Process Citation].

Journal Article Med Mal Infect · June 2014 Full text Link to item Cite

Community-based HCV screening: Knowledge and attitudes in a high risk urban population

Journal Article BMC Infectious Diseases · March 10, 2014 Background: In an attempt to curtail the rising morbidity and mortality from undiagnosed HCV (hepatitis C virus) in the United States, screening guidelines have been expanded to high-risk individuals and persons born 1945-1965. Community-based screening ma ... Full text Cite

Community-based HCV screening: knowledge and attitudes in a high risk urban population.

Journal Article BMC Infect Dis · February 10, 2014 BACKGROUND: In an attempt to curtail the rising morbidity and mortality from undiagnosed HCV (hepatitis C virus) in the United States, screening guidelines have been expanded to high-risk individuals and persons born 1945-1965. Community-based screening ma ... Full text Open Access Link to item Cite

A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design.

Journal Article Trials · January 22, 2014 BACKGROUND: The proportion of clinical research sponsored by industry will likely continue to expand as federal funds for academic research decreases, particularly in the fields of HIV/AIDS and hepatitis C (HCV). While HIV and HCV continue to burden the US ... Full text Open Access Link to item Cite

VISION: a regional performance improvement initiative for HIV health care providers.

Journal Article J Contin Educ Health Prof · 2014 INTRODUCTION: VISION (HIV Integrated Learning ModuleS: Achieving Performance Improvement through CollaboratiON) was a regional performance improvement (PI) continuing medical education (CME) initiative designed to increase guideline-conforming practice of ... Full text Link to item Cite

Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.

Journal Article Curr HIV/AIDS Rep · December 2013 Hepatitis C (HCV) coinfection is the leading cause of liver-related morbidity and is a leading cause of mortality in human immunodeficiency virus (HIV)-infected individuals in the antiretroviral therapy era. Direct-acting antiviral (DAA) therapies are tran ... Full text Link to item Cite

Management of hepatitis C virus infection: the basics.

Journal Article Top Antivir Med · December 2012 Chronic hepatitis C virus (HCV) infection affects some 170 million people worldwide, including 3 to 4 million in the United States who are largely unaware of their infection status. HCV has 6 genotypes; genotype 1 is the most common in the United States an ... Link to item Cite

IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.

Journal Article J Med Virol · October 2012 Recent studies have demonstrated that IL28B polymorphisms predict therapeutic responses in chronic hepatitis C virus (HCV)-treated patients; however, the effect on HCV viral diversity, particularly on the HCV protease gene, is not clear. This study sought ... Full text Link to item Cite

Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection.

Journal Article AIDS Patient Care STDS · September 2012 Abstract Health care utilization for HIV-1-infected patients appears to be declining in the United States as a result of highly active antiviral therapy (HAART); yet the opposite appears true in the HIV/hepatitis C virus (HCV) coinfected population. The re ... Full text Link to item Cite

The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.

Journal Article Dig Dis Sci · August 2012 BACKGROUND: Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined. AIM: We sought to validate thes ... Full text Link to item Cite

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Journal Article Hepatology · August 2012 UNLABELLED: Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (P ... Full text Link to item Cite

ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.

Journal Article J Med Virol · July 2012 Published studies have described a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and ribavirin (RBV)-induced hemolytic anemia in HCV-infected patients receiving pegylated interferon ( ... Full text Link to item Cite

Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.

Journal Article J Viral Hepat · May 2012 Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection. IL28B has been linked with LDL-C ... Full text Link to item Cite

Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

Journal Article Gastroenterology · May 2012 With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity and mortality among patients with both infections (coinfection). In addition to the high prevale ... Full text Link to item Cite

Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.

Journal Article J Antimicrob Chemother · May 2012 OBJECTIVES: The mechanism explaining the strong association between IL28B rs12979860 polymorphisms and treatment outcome in chronic hepatitis C remains unclear. We explore whether IL28B protein [interferon (IFN)-λ3] plasma levels may vary according to IL28 ... Full text Link to item Cite

An integrated alcohol abuse and medical treatment model for patients with hepatitis C.

Journal Article Dig Dis Sci · April 2012 BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment. AIMS: This prospective cohort study examined the feasibi ... Full text Open Access Link to item Cite

Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis.

Journal Article J Viral Hepat · April 2012 Cytokeratin-18 (CK-18) is a major intermediate filament protein in liver cells. The M30 fragment of CK-18 has been identified as a useful marker of apoptosis associated with fibrosis and steatosis in nonalcoholic steatohepatitis (NASH). We sought to assess ... Full text Link to item Cite

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.

Journal Article J Hepatol · February 2012 BACKGROUND & AIMS: Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related ... Full text Link to item Cite

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.

Journal Article J Infect Dis · February 1, 2012 BACKGROUND: A recent genome-wide association study reported a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate (ITPA) gene and hemolytic anemia in patients infected with hepatitis C virus (HCV) receiving pegylated ... Full text Link to item Cite

The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents.

Journal Article Eur Gastroenterol Hepatol Rev · 2012 The new era of Hepatitis C management is marked by newly available tests for IL28B polymorphisms, US Food and Drug Administration (FDA) approval of the first direct acting antivirals (DAA; boceprevir and telaprevir), monitoring of drug-related mutations an ... Link to item Cite

Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study.

Journal Article PLoS One · 2012 OBJECTIVE: To determine the feasibility and case detection rate of a geographic information systems (GIS)-based integrated community screening strategy for tuberculosis, syphilis, and human immunodeficiency virus (HIV). DESIGN: Prospective cross-sectional ... Full text Open Access Link to item Cite

The role of IL28B genotype testing in the era of direct acting antiviral agents

Journal Article European Gastroenterology and Hepatology Review · January 1, 2012 The new era of Hepatitis C management is marked by newly available tests for IL28B polymorphisms, US Food and Drug Administration (FDA) approval of the first direct acting antivirals (DAA; boceprevir and telaprevir), monitoring of drug-related mutations an ... Cite

Feasibility and willingness-to-pay for integrated community-based tuberculosis testing.

Journal Article BMC Infect Dis · November 2, 2011 BACKGROUND: Community-based screening for TB, combined with HIV and syphilis testing, faces a number of barriers. One significant barrier is the value that target communities place on such screening. METHODS: Integrated testing for TB, HIV, and syphilis wa ... Full text Open Access Link to item Cite

Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

Journal Article J Infect Dis · June 1, 2011 BACKGROUND: Single-nucleotide polymorphisms (SNPs) near the IL28B gene have recently been associated with spontaneous hepatitis C virus (HCV) clearance and response to interferon-based therapies in patients with chronic hepatitis C. Because human immunodef ... Full text Link to item Cite

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.

Journal Article AIDS · May 15, 2011 BACKGROUND: A single nucleotide polymorphism (SNP) upstream of the IL28B gene (rs12979860) predicts sustained virological response (SVR) to peginterferon-ribavirin therapy in chronic hepatitis C patients. There is scarce information regarding the influence ... Full text Link to item Cite

Immune reconstitution syndrome in a patient with disseminated histoplasmosis and steroid taper: maintaining the perfect balance.

Journal Article Mycoses · May 2011 Immune reconstitution syndrome (IRS) is an increasingly common condition that has been described in immunosuppressed individuals once immune function is restored. In this case, we describe a patient who had a renal transplant and subsequently developed pul ... Full text Link to item Cite

Investigational Agents for Chronic Viral Infections: HIV and HCV

Journal Article JOURNAL OF NEUROIMMUNE PHARMACOLOGY · April 1, 2011 Link to item Cite

A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.

Journal Article Am J Med · March 2011 BACKGROUND: The epidemiology of community-associated Clostridium difficile infection is not well known. We performed a multicenter, case-control study to further describe community-associated C. difficile infection and assess novel risk factors. METHODS: W ... Full text Link to item Cite

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Journal Article Hepatology · February 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepati ... Full text Link to item Cite

Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline.

Journal Article AIDS · January 14, 2011 The critical role of interleukin-28B (IL28B)/interferon-λ3 (IFN-λ3) polymorphisms on the susceptibility to hepatitis C virus infection and the response to peginterferon-ribavirin therapy has encouraged exploration of similar effects on other viruses. Given ... Full text Link to item Cite

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

Journal Article Clin Infect Dis · November 15, 2010 BACKGROUND: A single-nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) strongly predicts sustained virological response to pegylated interferon plus ribavirin (pegIFN-RBV) treatment for chronic hepatitis C virus (HCV) infection. Given that the ... Full text Link to item Cite

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Journal Article Gastroenterology · October 2010 BACKGROUND & AIMS: In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic ane ... Full text Link to item Cite

Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.

Journal Article J Antimicrob Chemother · October 2010 Chronic hepatitis C virus (HCV) infection is a global health problem, but the current therapy is effective in <50% of patients infected with genotype 1. With advances in cell culture systems over the past decade, the development of directly acting antivira ... Full text Link to item Cite

Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States.

Journal Article AIDS Patient Care STDS · September 2010 Knowing one's HIV status is particularly important in the setting of recent tuberculosis (TB) exposure. Blood tests for assessment of tuberculosis infection, such as the QuantiFERON Gold in-tube test (QFT; Cellestis Limited, Carnegie, Victoria, Australia), ... Full text Open Access Link to item Cite

Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA.

Journal Article Infection · August 2010 BACKGROUND: There is increasing recognition of the importance of community-associated Clostridium difficile infection (CA-CDI) despite little being known about its epidemiology. METHODS: We performed routine, active laboratory surveillance for CDI at the D ... Full text Link to item Cite

Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.

Journal Article J Antimicrob Chemother · June 2010 The introduction of protease inhibitors (PIs) to HIV treatment combinations in 1996 has significantly reduced morbidity and mortality due to HIV infection. Since the 1990s, multiple PIs have been approved, with several boosted PI regimens recognized as fir ... Full text Link to item Cite

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

Journal Article AIDS · May 15, 2010 BACKGROUND: Given that peginterferon-ribavirin treatment is poorly tolerated, there is interest in the identification of predictors of response, particularly in HIV/hepatitis C virus (HCV)-coinfected patients that respond less than HCV-monoinfected individ ... Full text Link to item Cite

Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA.

Journal Article Emerg Infect Dis · February 2010 We determined estimated incidence of and risk factors for community-associated Clostridium difficile infection (CA-CDI) among patients treated at 6 North Carolina hospitals. CA-CDI case-patients were defined as adults (>18 years of age) with a positive sto ... Full text Open Access Link to item Cite

Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis.

Journal Article Clin Chest Med · June 2009 Emerging fungi previously thought to be nonpathogenic are now recognized as playing a significant role in the increased incidence of invasive fungal disease. This change in the epidemiology of invasive fungal infections (IFIs) has occurred in the era of ag ... Full text Link to item Cite

Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005.

Journal Article Infect Control Hosp Epidemiol · March 2008 OBJECTIVE: To determine the timing of community-onset Clostridium difficile-associated disease (CDAD) relative to the patient's last healthcare facility discharge, the association of postdischarge cases with healthcare facility-onset cases, and the influen ... Full text Link to item Cite

Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population.

Journal Article AIDS Res Hum Retroviruses · October 2007 Clinical criteria are recommended to select HIV-infected patients for initiation of antiretroviral therapy when CD4 lymphocyte testing is unavailable. We evaluated the performance characteristics of WHO staging criteria, anthropometrics, and simple laborat ... Full text Link to item Cite

Human interleukin-2 production in insect (Trichoplusia ni) larvae: effects and partial control of proteolysis.

Journal Article Biotechnol Bioeng · January 20, 1999 Many eukaryotic proteins have been successfully expressed in insect cells infected with a baculovirus in which the foreign gene has been placed under the control of a viral promoter. This system can be costly at large scale due to the quality of virus stoc ... Full text Link to item Cite

Appearance of protease activities coincides with p10 and polyhedrin-driven protein production in the baculovirus expression system: effects on yield.

Journal Article Biotechnol Prog · 1998 A study of proteolysis effects on recombinant protein yield was completed using the insect cell (Sf-9)-baculovirus (AcNPV) expression system. Activities of protease and beta-galactosidase (beta-gal), a marker heterologous protein, were assayed at various m ... Full text Link to item Cite

Substrate (gelatin) gel electrophoretic method for analysis of protease activity in insect (Sf-9) cells

Journal Article Biotechnology Techniques · January 1, 1997 A method for detection, quantification, and characterization of protease activities present in the insect cell/baculovirus protein expression system was demonstrated. Proteases were found of 39, 44, and 52 kDa molecular weight. Enzymatic inhibitors (antipa ... Full text Cite

Elicitation of protease activity in insect (Spodoptera frugiperda) cell cultures

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · March 24, 1996 Link to item Cite